Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.47 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.47 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.47 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.47 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.47 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.47 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.47 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332336 | 1.00 | DNM1 (0.79) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Benzododecinium SCHEMBL331784 | 1.00 | DNM1 (0.79) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL330866 | 1.00 | DNM1 (0.79) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Cetalkonium SCHEMBL1868434 | 1.00 | DNM1 (0.79) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Sulfuric Acid SCHEMBL2968768 | 0.95 | DNM1 (0.81) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Cetalkonium SCHEMBL14965272 | 0.95 | DNM1 (0.81) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Benzododecinium SCHEMBL11412384 | 0.95 | DNM1 (0.81) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| Benzododecinium SCHEMBL330693 | 0.94 | DNM1 (0.79) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL330483 | 0.94 | DNM1 (0.79) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL330707 | 0.94 | DNM1 (0.79) | DNM1MEN1KMT2AMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180087005-A1 | Fragrance Compositions Comprising Ionic Liquids | THE PROCTER & GAMBLE COMPANY | 2018-03-29 | — | — | US | disclosed |
| US-9840680-B2 | Fragrance compositions comprising ionic liquids | THE PROCTER & GAMBLE COMPANY (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160115424-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | THE PROCTER & GAMBLE COMPANY | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115424-A1 | FRAGRANCE COMPOSITIONS COMPRISING IONIC LIQUIDS | CUTA, TRPA1, POLR1C | ADRB2 3001/4885HTR1A 738/4885ADRA2A 3408/4885 |
| US-20180087005-A1 | Fragrance Compositions Comprising Ionic Liquids | CUTA, TRPA1, POLR1C | ADRB2 3001/4885HTR1A 738/4885ADRA2A 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.